|
Orthologous residues
|
|
ATF‑1 (human): S63‑p, ATF‑1 (mouse): S63‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
brain cancer, glioblastoma, glioblastoma multiforme, glioma
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), 3T3 (fibroblast), T98G (glial)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human, mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
CDK3 (human)
|
modification site within consensus motif, transfection of wild-type enzyme, phospho-antibody, co-immunoprecipitation, pharmacological activator of upstream enzyme, siRNA inhibition of enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
EGF
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
cell growth, altered, transcription, altered
|
